{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:24:06Z","timestamp":1789788246928,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejso.2017.01.015","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T06:46:54Z","timestamp":1486104414000},"page":"1095-1101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: Toward routine preoperative dosage of Von Willebrand factor?"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3123","authenticated-orcid":false,"given":"J.-B.","family":"Delhorme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Severac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Triki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Romain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Grunebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ejso.2017.01.015_bib1","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2017.01.015_bib2","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2017.01.015_bib3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jso.23722","article-title":"American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer","volume":"110","author":"Esquivel","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2017.01.015_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2017.01.015_bib5","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2017.01.015_bib6","first-page":"456","article-title":"Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy","volume":"36","author":"Elias","year":"2010","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"24","key":"10.1016\/j.ejso.2017.01.015_bib7","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2017.01.015_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/bjs.7263","article-title":"Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma","volume":"98","author":"Chua","year":"2011","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.ejso.2017.01.015_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","article-title":"The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"20","author":"Deraco","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"10.1016\/j.ejso.2017.01.015_bib10","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2017.01.015_bib11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2017.01.015_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution","volume":"13","author":"Elias","year":"2002","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"issue":"1","key":"10.1016\/j.ejso.2017.01.015_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.suronc.2014.12.002","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis","volume":"24","author":"Hubert","year":"2015","journal-title":"Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2017.01.015_bib14","first-page":"589","article-title":"Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study","volume":"36","author":"Pomel","year":"2010","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ejso.2017.01.015_bib15","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-016-5143-1","article-title":"Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors","author":"Charrier","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2017.01.015_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U","article-title":"Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis","volume":"14","author":"Sugarbaker","year":"1998","journal-title":"Semin Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2017.01.015_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ejso.2017.01.015_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00534-005-0999-7","article-title":"Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system","volume":"12","author":"Strasberg","year":"2005","journal-title":"J\u00a0Hepatobiliary Pancreat Surg"},{"issue":"2","key":"10.1016\/j.ejso.2017.01.015_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"Suppl. 1","key":"10.1016\/j.ejso.2017.01.015_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ijlh.12346","article-title":"Laboratory testing for platelet function disorders","volume":"37","author":"Israels","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.ejso.2017.01.015_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1477-7819-12-332","article-title":"Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis","volume":"12","author":"Marcotte","year":"2014","journal-title":"World J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2017.01.015_bib22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jso.23431","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer: HIPEC-OX peritoneal carcinomatosis","volume":"108","author":"Gervais","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2017.01.015_bib23","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1245\/s10434-012-2264-z","article-title":"The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study","volume":"19","author":"Hompes","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2017.01.015_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/141585","article-title":"Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC","volume":"2012","author":"Sammartino","year":"2012","journal-title":"Gastroenterol Res Pract"},{"issue":"9","key":"10.1016\/j.ejso.2017.01.015_bib25","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1245\/s10434-014-3713-7","article-title":"Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis","volume":"21","author":"Ceelen","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2017.01.015_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s003840100345","article-title":"Von Willebrand factor in colorectal cancer","volume":"17","author":"Damin","year":"2002","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"10.1016\/j.ejso.2017.01.015_bib27","first-page":"445","article-title":"The clinical value of Von Willebrand factor in colorectal carcinomas","volume":"3","author":"Schellerer","year":"2011","journal-title":"Am J Transl Res"},{"issue":"14","key":"10.1016\/j.ejso.2017.01.015_bib28","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3748\/wjg.v11.i14.2166","article-title":"Plasma Von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma","volume":"11","author":"Wang","year":"2005","journal-title":"World J Gastroenterol WJG"},{"issue":"3","key":"10.1016\/j.ejso.2017.01.015_bib29","first-page":"805","article-title":"The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits","volume":"10","author":"Cwikiel","year":"1996","journal-title":"Scanning Microsc"},{"issue":"1","key":"10.1016\/j.ejso.2017.01.015_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/sca.4950230101","article-title":"Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation","volume":"23","author":"Kinhult","year":"2001","journal-title":"Scanning"},{"issue":"12","key":"10.1016\/j.ejso.2017.01.015_bib31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1463-1318.2012.03049.x","article-title":"The structure of the Von Willebrand factor is not altered in patients with colorectal carcinoma: the Von Willebrand factor in colorectal carcinoma","volume":"14","author":"Weiss","year":"2012","journal-title":"Colorectal Dis"},{"issue":"6","key":"10.1016\/j.ejso.2017.01.015_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jso.23228","article-title":"Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis: HIPEC with oxaliplatin","volume":"107","author":"Glockzin","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2017.01.015_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jso.23546","article-title":"The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study: oxaliplatin or MMC in HIPEC","volume":"109","author":"Hompes","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2017.01.015_bib34","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23728","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery: ASPSM comparison of HIPEC with MMC vs. Oxaliplatin","volume":"110","author":"Prada-Villaverde","year":"2014","journal-title":"J\u00a0Surg Oncol"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798317301105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798317301105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T13:20:33Z","timestamp":1536067233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798317301105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0748798317301105"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2017.01.015","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: Toward routine preoperative dosage of Von Willebrand factor?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2017.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}